Giving labs the tools to be successful

5 questions with Douglas Storts
Laurel Oldach
Dec. 18, 2020

For almost three decades, Douglas Storts has been developing tools for genetic amplification at the reagent supply company Promega in Madison, Wisconsin. "I've enjoyed working on lots of projects," he said. "There's been a huge variety over the years."


Name: Douglas Storts

Current position: Head of Research, Nucleic Acid Technologies, Promega Corporation

Career path: Ph.D., microbiology, Miami University, 1980
Postdoctoral research: University of Chicago

First job outside of academia: Ambion, a molecular biology startup in Austin, Texas

Favorite molecule: DNA

According to Storts, the throughline that ties his group's work on genetic changes in astronauts to cancer diagnostics is that they always are working to solve puzzles. ASBMB Today caught up with him for the latest in our series on industry careers. This interview has been condensed and edited.

As the head of research in nucleic acids at Promega, what do you work on?

I manage a group of about two dozen scientists working on projects related to nucleic acid amplification and genotyping. The products we develop are used for forensic testing, molecular diagnostics and also in the life science research community. We develop tools that we can give to laboratories across the world and enable them to be successful.

What's most challenging about your work?

With some of these assays, we're looking at 30 or more different targets in the genome in a single amplification reaction that has to be extremely robust and extremely efficient. We need to reliably detect copies of DNA every time, time after time. In forensic tests, the samples are almost unimaginable. Whatever they find at a crime scene, in whatever quantity, they want to test it: telephones, bloodspots, bodies — anything.

How did you come to work at Promega?

I recognized early on that I was not interested in an academic position. After I received my Ph.D. and did a postdoc, I went to a small startup company in Austin, Texas, for about two years. I transferred to Promega in 1991 based on a recommendation from a recruiter. I have not looked back.

What traits do you look for in a potential hire?

No. 1 skill: communication. It would be great to have somebody come in with a technical background exactly aligned with what I need. That rarely happens. So what I want is somebody who has good communication skills who can take direction without being offended and can reach out for help when they have any questions. I can teach anyone to do almost anything. They have to be able to listen.

This second skill is being able to think outside the box. If somebody thinks A plus B must equal C, then if A plus B equals anything other than C, they're totally flustered. When you show them they've walked into this with a box around their thoughts and the data clearly indicate the answer lies outside of the box, they begin to understand: You've got to think outside the box to solve complex problems.

What career advice do you give young scientists?

Work hard. Be creative. Be a team member. My perception is there are a lot of folks that have a big gap in one of those three areas.

(Would you like to suggest an ASBMB member who works in industry for a Five Questions interview? Send an email to ASBMB Today.)

Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Industry

Industry highlights or most popular articles

Biotech industry jargon: A primer for the curious
Professional Development

Biotech industry jargon: A primer for the curious

July 29, 2021

The specific scientific and technical knowledge you need in an industry job depends on the role and will change over the course of your career. But it can help to know the basics.

A primer on performance reviews in industry

A primer on performance reviews in industry

July 16, 2021

Our industry careers columnist provides an overview of what you can expect and how to handle a lukewarm or negative review.

Why is the FDA funded in part by the companies it regulates?

Why is the FDA funded in part by the companies it regulates?

July 4, 2021

The U.S. Food and Drug Administration receives almost half its funding from companies it regulates, such as drug and medical device makers. Is this something you should be concerned about?

Out for blood in the search to stall aging

Out for blood in the search to stall aging

July 3, 2021

A gaggle of biotech startups are trying vastly different approaches to spin animal studies into the next big anti-aging therapy. It’s too early to know which, if any, will succeed.

Climbing the research ladder in industry

Climbing the research ladder in industry

June 25, 2021

Our industry careers columnist offers brief descriptions of entry-level, mid-level and senior-level positions in the R&D world.

Targeting 20,000 proteins by 2035

Targeting 20,000 proteins by 2035

May 26, 2021

The organizers of Target 2035, the Structural Genome Consortium, have an ambitious aim: to invent an inhibitor or probe for every protein in the human proteome by 2035. How will they do it?